Page last updated: 2024-12-06

rilmakalim

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

rilmakalim: potassium channel opener; rimalkalim may be a typo [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65966
CHEMBL ID275758
SCHEMBL ID221620
MeSH IDM0202274

Synonyms (23)

Synonym
rilmakalim [inn]
rilmakalim
(+)-1-((3s,4r)-3-hydroxy-2,2-dimethyl-6-(phenylsulfonyl)-4-chromanyl)-2-pyrrolidinone
rilmakalimum [inn-latin]
rilmakalime [inn-french]
2-pyrrolidinone, 1-(3,4-dihydro-3-hydroxy-2,2-dimethyl-6-(phenylsulfonyl)-2h-1-benzopyran-4-yl)-, (3s-trans)-
hoe-234
1-[(3s,4r)-6-(benzenesulfonyl)-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]pyrrolidin-2-one
CHEMBL275758
rilmakalime
132014-21-2
47y56t6lei ,
unii-47y56t6lei
rilmakalimum
SCHEMBL221620
AKOS022180807
3,4-dihydro-2,2-dimethyl-6-phenylsulfonyl-trans-4-(2-oxo-1-pyrrolidinyl)-2h-benzo[b]pyran-3-ol
LKAQWOWWTKFLNX-UXHICEINSA-N
DTXSID60157307
bdbm50474006
1-[(3s,4r)-3-hydroxy-2,2-dimethyl-6-phenylsulfonyl-3,4-dihydrochromen-4-yl]pyrrolidin-2-one
1-((3s,4r)-3-hydroxy-2,2-dimethyl-6-(phenylsulfonyl)chroman-4-yl)pyrrolidin-2-one
Q27259086

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" After activation of ATP-sensitive K+ channels by 1 microM of (3S,4R)-3-hydroxy-2,2-dimethyl-4-(oxo-1 pyrrolidinyl)-6-phenyl-sulfonylchroman hemihydrate (HOE 234) the dose-response curves for isoprenaline were shifted to the right (about 9-fold)."( Modulation of the contractility of guinea pig papillary muscle by the activation of ATP-sensitive K+ channels.
Kocić, I, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID197351Dilator activity expressed as potency for relaxation of Tracheal strips percontracted with 0.6 uM carbachol2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
6-Sulfonylchromenes as highly potent K(ATP)-channel openers.
AID174888Difference between the pEC50 values in rat aorta and trachea as an indicator of selectivity2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
6-Sulfonylchromenes as highly potent K(ATP)-channel openers.
AID208992Binding affinity towards Sulfonylurea receptor 2B (SUR2B) in cultured rat aortic smooth muscle cells (SMC)2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
6-Sulfonylchromenes as highly potent K(ATP)-channel openers.
AID197350Dilator activity expressed as potency for relaxation of Aortic rings precontracted with 25 mM K2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
6-Sulfonylchromenes as highly potent K(ATP)-channel openers.
AID180022Maximum level of relaxation of aortic rings measured as percentage of basal tension.2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
6-Sulfonylchromenes as highly potent K(ATP)-channel openers.
AID208988Binding affinity to the sulfonylurea receptor 2A (SUR2A) in purified membranes of rat-heart myocytes2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
6-Sulfonylchromenes as highly potent K(ATP)-channel openers.
AID180023Maximum level of relaxation of tracheal strips measured as percentage of basal tension2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
6-Sulfonylchromenes as highly potent K(ATP)-channel openers.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's18 (60.00)18.2507
2000's11 (36.67)29.6817
2010's1 (3.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.60 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other34 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]